Regulatory filings appear to be the next step for the LAMA/LABA bronchodilator combination of umeclidinium bromide (UMEC, or GSK573719) and vilanterol (VI), under development by GlaxoSmithKline plc and longtime partner Theravance Inc. The companies reported top-line results early Monday indicating the first four of seven Phase III studies of the investigational therapy showed superiority against both placebo and current standard of care in chronic obstructive pulmonary disease (COPD).